Novartis raises 2026 profit outlook as drug sales offset $1.9 billion impairment
Novartis (NYSE:NVS) raised its 2026 core operating income outlook after Q3 sales growth and margin improvements. Q3 net sales rose 4% to $14.5B, core operating income up 10% to $6B. Impairment of $1.9B for del-desiran led to a 61% drop in reported operating income. Key drugs like Kisqali, Kesimpta, Scemblix, and Leqvio drove growth.
How this was made
The 30-second read
Why it matters
The guidance raise offsets the impairment impact, suggesting resilient core operations.
Market read
Guidance upgrade for a major pharma player is likely to move the stock and influence sector sentiment.
What to watch
The $1.9 bn impairment and missed trial for del‑desiran may weigh on longer‑term sentiment.
Background
Novartis reported Q3 results with mixed performance: strong sales growth in key drugs but a large impairment from a failed trial.
Ticker impact
Novartis raised its 2026 core operating income outlook, shifting from a projected decline to flat or low single‑digit growth.
likely upside as investors price in improved operating income outlook
The new guidance is a primary disclosure with material financial numbers for a large‑cap pharma company.
Market effects
Other pharma and biotech stocks may see modest support as the sector benefits from a major player’s improved outlook.
European markets could see a lift in healthcare indices.
Global biotech investors may adjust expectations for pipeline valuations.
Counterpoint
If the impairment charge signals deeper pipeline risks, the upgrade could be short‑lived.
Key entities
- companyNovartis AG
Swiss pharmaceutical group, ticker NVS.
